Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.
about
Genetic insights into the mechanisms of Fgf signalingRoles of FGF Signals in Heart Development, Health, and DiseaseInhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels.Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis.Hepatic gene therapy rescues high-fat diet responses in circadian Clock mutant mice.Quantitative liver proteomics identifies FGF19 targets that couple metabolism and proliferation.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).Multiple faces of fibroblast growth factor-23Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.Vascular Endothelial Regulation of Obesity-Associated Insulin Resistance.FGFs: crucial factors that regulate tumour initiation and progression.The ever-expanding myokinome: discovery challenges and therapeutic implications.Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus.New therapeutic concepts in bile acid transport and signaling for management of cholestasis.Macronutrient Intake-Associated FGF21 Genotype Modifies Effects of Weight-Loss Diets on 2-Year Changes of Central Adiposity and Body Composition: The POUNDS Lost Trial.Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.Fibroblast Growth Factors in the Gastrointestinal Tract: Twists and Turns.Advances and challenges in targeting FGFR signalling in cancer.Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.FGF1 - a new weapon to control type 2 diabetes mellitus.Fasting-induced hormonal regulation of lysosomal function.Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer.Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism.Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families.Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System.Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment.Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).Antibody-Mediated Targeting of the FGFR1c Isoform Increases Glucose Uptake in White and Brown Adipose Tissue in Male Mice.Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice.AhR and SHP regulate phosphatidylcholine and S-adenosylmethionine levels in the one-carbon cycle.Highly selective and sensitive measurement of active forms of FGF21 using novel immunocapture enrichment with LC-MS/MS.Taming the Flames: Targeting White Adipose Tissue Browning in Hypermetabolic Conditions.Ablation of FGFR2 in Fibroblasts Ameliorates Kidney Fibrosis after Ischemia/Reperfusion Injury in Mice.Structures of β-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling.Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.A novel zebrafish intestinal tumor model reveals a role for cyp7a1-dependent tumor-liver crosstalk in tumor's adverse effects on host.Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice.The role of adipokines in skeletal muscle inflammation and insulin sensitivity.
P2860
Q28066570-CCCFE3C9-00A5-440F-B779-B83BF990B22EQ28072691-1545DBF9-8AA0-40FB-913F-F0CD1780431AQ33611054-69D1486B-43CE-4FC9-A49F-898B18755B0BQ33716459-B3B0E899-568B-400B-9175-57D7044130DAQ33726505-A2125C4A-9B79-410A-8918-6DEBF7E111E1Q36274229-83E1CF33-BB19-4B42-9B93-468A11A067E7Q36983860-E628F353-CFAF-49EB-9BA9-D5A4F58FF893Q37312020-396FA581-ED30-4553-8CBE-19E890F62C6DQ37628912-5522B551-29B1-4CE7-8944-072EFF412C3AQ38636437-EEC1864E-2397-4680-B637-C12A06D39F57Q38887615-CA73D4CB-D407-44DC-BCBF-6E4C081D2532Q38951385-770E7EDE-D33F-4340-A50E-07F7A7D905E9Q39026412-A25381CB-B668-45C7-9447-9F9E352D3F14Q39044702-AFA98D86-0722-4F3A-801C-42FED78D1759Q39062369-AEAA2609-3F7A-4F59-8942-4BA2128FE0BBQ39126658-99C70EC6-292A-4E04-AE61-646D0FB726F7Q39136136-1BCB2EA3-6F9A-49CC-BCDF-993B7351E889Q39183442-AE2A3B62-79CE-4852-B91E-F5E8CDD2E24BQ39377977-7EB1C091-352A-4385-B387-86118C80362AQ39406663-408DFA72-543D-4334-AB82-07C1FAA311C7Q41070270-02C9B865-86F8-46E9-B412-5142826FE682Q41835918-1E0DE746-BDDB-4F85-8911-BD173E08096BQ42127073-A324552C-23C7-431C-ABD8-51345425903DQ45784223-19119BCB-8BC7-43D7-A565-17EF58C1D007Q47135121-FC4D0605-067C-4F10-8D91-BCA65B16B771Q47157299-9F3B1BFD-E161-46C1-8637-D8E0331D3F24Q47246053-BE034A57-55F6-495B-AFC6-7AA41AB01259Q47761014-965441E7-6C60-4EAD-8F61-9019D7360A28Q47779219-2A738B51-F02C-4438-96C4-1CF12D6DACAAQ47887075-4846DC6B-50C0-4E4F-920C-F7633E825B57Q48222795-8BB95CB8-7A2C-4CD0-BAC2-D0F576A541E6Q49500923-97046D45-32E0-4D1C-9CC1-DEF8C05AA2E5Q49846751-A1BC5614-0858-4FD3-AD4C-BEF0CF21AD82Q49921559-746E45AE-DEF9-419C-9FB1-ACC8C234E6E3Q49982519-40D4C292-1688-4190-B7E0-7A469D351C57Q50001768-A1AC3171-184C-4863-B8BA-EE93C4FD5896Q52428984-4B07D8E1-BFDA-401D-B3F2-A40DDE8CF01BQ52625090-7CA030A7-25E9-4EAF-A4E2-DA4D6628BBCBQ52699090-B0051D16-2792-463E-9CFB-50DA48590A3FQ53682459-5C79A8AE-F25F-4834-A6D3-7A48CFE2147D
P2860
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.
@en
type
label
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.
@en
prefLabel
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.
@en
P2093
P2860
P356
P1476
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.
@en
P2093
Antonio Moschetta
Carlo Sabbà
Chiara Degirolamo
P2860
P2888
P356
10.1038/NRD.2015.9
P577
2015-11-16T00:00:00Z